From:
`Sent:
`To:
`Cc:
`
`Subject:
`Attachments:
`
`Deborah Sterling <DSTERLING@sternekessler.com>
`Thursday, November 21, 2019 8:54 PM
`Precedential_Opinion_Panel_Request
`Trials; 'william.raich@finnegan.com'; 'erin.sommers@finnegan.com';
`'yieyie.yang@finnegan.com'; 'john.williamson@finnegan.com';
`'pier.deroo@finnegan.com'; 'stewart_mark@lilly.com'; 'jivraj_sanjay@lilly.com'; Bob
`Millonig; Gaby Longsworth; Olga A. Partington; Dennies Varughese; Jeremiah B.
`Frueauf
`Recommendation for POP Review
`IPR2018-01712 Request for Rehearing.pdf; IPR2018-01711 Request for Rehearing.pdf;
`IPR2018-01710 Request for Rehearing.pdf; IPR2018-01427 Request for Rehearing.pdf;
`IPR2018-01426 Request for Rehearing.pdf; IPR2018-01425 Request for Rehearing.pdf;
`IPR2018-01424 Request for Rehearing.pdf; IPR2018-01423 Request for Rehearing.pdf;
`IPR2018-01422 Request for Rehearing.pdf
`
`To the Precedential Opinion Panel of the Board,
`
`Patent Owner respectfully recommends that the Precedential Opinion Panel review the attached Requests for Rehearing 
`under 37 C.F.R. 41.71(d) filed today, November 21, 2019, in proceeding numbers IPR2018‐01422, ‐01423, ‐01424, ‐
`01425, ‐01426, and ‐01427 and IPR2018‐01710, ‐01711, and ‐01712. These Requests for Rehearing are being filed within 
`14 days from the panel’s denial of authorization for supplemental briefing addressing Arthrex and denial of authorization 
`to file a motion for stay, issued by email from the Board on November 15, 2019. Counsel for Petitioners are recipients to 
`this email, a courtesy copy of which is also being sent to Trials@uspto.gov.
`
`Statement of Counsel
`
`Based on my professional judgment, I believe the Board panel decision is contrary to the following constitutional 
`provision, statute, or regulation: Appointments Clause, U.S. Const., art. II, section 2, cl. 2; Fed. R. App. P. 41(c); 5 U.S.C. § 
`551 et seq.
`
`Based on my professional judgment, I believe this case also requires an answer to one or more precedent‐setting 
`questions of exceptional importance:
`
`1. The Board’s response to, and implementation of, Arthrex, Inc. v. Smith & Nephew, Inc., — F.3d —, 2019 WL
`5616010 (Fed. Cir. Oct. 31, 2019), in pending cases concerns “major policy [and] procedural issues” for which “it
`is appropriate to create . . . binding agency authority through adjudication before the Board.”  SOP 2 at 3.
`
`2. Whether the Appointments Clause violation has been fixed prior to the mandate issuing in Arthrex, and whether
`decisions made in pending cases by APJs whose appointments violated the constitution must be vacated.  SOP at
`4.
`
`Reasons for Recommending Precedential Opinion Panel Review
`
`Arthrex held that Administrative Patent Judges have not been properly appointed, in violation of the Appointments 
`Clause, and struck down their removal protections to remedy that constitutional violation.  But the mandate in Arthrex 
`has not issued, and until it does the Arthrex remedy is not effective and Administrative Patent Judges will not be 
`removable at‐will. Pressing forward with a hearing and decision in this IPR before the mandate issues would repeat the 
`constitutional violation Arthrex identified. That would be a tremendous waste of resources by the Board and the parties.
`IPR2018-01422-01427, -01710-01712
`Ex. 3002
`
`1
`
`

`

`Patent Owner sought to raise these issues in supplemental briefing, in which it could explain the impact of Arthrex and 
`the constitutional violation that would occur from proceeding with this case, and requested authorization to move for a 
`stay. The Board by email denied Patent Owner authorization to file such briefing or a motion to stay without providing 
`Patent Owner with an opportunity to be heard in a conference call to discuss these issues.   
`
`Respectfully Submitted,
`Deborah Sterling
`(Lead Counsel for Patent Owner)
`
`Deborah Sterling, Ph.D.
`Director
`Sterne, Kessler, Goldstein & Fox P.L.L.C.
`1100 New York Avenue, NW, Washington, DC 20005
`
`Email: dsterling@sternekessler.com
`Direct: 202.772.8501
`
`IP Assistant: Katherine Valencia
`Direct: 202.772.8937 Main: 202.371.2600
`
`
`
`Notice: The information in this electronic transmission (including any attachments) may contain
`confidential or legally privileged information and is intended solely for the individual(s) or entity(ies)
`named above. If you are not an intended recipient or an authorized agent, you are hereby notified
`that reading, distributing, or otherwise disseminating or copying, or taking any action based on the
`contents of this transmission is strictly prohibited. Any unauthorized interception of this transmission
`is illegal under the law. If you have received this transmission in error, please immediately notify the
`sender by return email and then destroy all copies of the transmission.
`
`2
`
`IPR2018-01422-01427, -01710-01712
`Ex. 3002
`
`